N/A
Completed N=295
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
Source: ClinicalTrials.gov NCT01108809 ↗Enrolled (actual)
295
Serious AEs
0.3%
Results posted
Sep 2012
Primary outcomePrimary: Change in Systolic Blood Pressure From Baseline to Study End — -39.2 mmHg
Summary
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Systolic Blood Pressure From Baseline to Study End |
-39.2 | — |
| PRIMARY Change in Diastolic Blood Pressure From Baseline to Study End |
-17.8 | — |
| PRIMARY Evolution of the Cardiovascular Risk Factor SCORE From Baseline to Study End |
64.8; 8.8; 0.3; 26.1 | — |
| PRIMARY Evolution of the Cardiovascular Risk Factor Framingham From Baseline to Study End |
58.3; 10.2; 0.3; 31.2 | — |
| PRIMARY Evolution of the European Society of Hypertension / European Society of Cardiology (ESH/ESC) Based Cardiovascular Risk Factor From Baseline to Study End |
65.1; 12.9; 0.3; 21.7 | — |
| SECONDARY Percentage of Patients That Achieve Target Blood Pressure Values According to the European Society of Hypertension/European Society of Cardiology (ESH/ESC) |
57.3 | — |
| SECONDARY Additional Antihypertensive Treatment Pattern at Visit 3 (End of Study) |
16.9; 34.8; 39.3; 75.1; 20.9 | — |
| SECONDARY Change in Heart Rate From Baseline to Study End |
-7.6 | — |
| SECONDARY Number of Participants Not Completing Study |
3; 1 | — |
| SECONDARY Number of Patients With Adverse Events (AE) |
4 | — |
Eligibility Criteria
Inclusion criteria
- diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
- at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease
Exclusion criteria
- hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market, as prescribed in the SPC
- pregnancy and lactation
- diseases involving biliary obstruction
- severe liver impairment
- severe hypertension
- malignant hypertension
- secondary hypertension
- patients age under 18 years
Data sourced from ClinicalTrials.gov (NCT01108809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.